The Perinatal Pharmacology Group

The perinatal period represents a critical developmental window during which the health and wellbeing of future generations is laid down. Led by Dr Adeniyi Olagunju, research within the Perinatal Pharmacology Group is focused on broadening our understanding of drug safety and efficacy during pregnancy and lactation. Working across three domains (human-relevant in vitro modelling, in silico modelling and clinical research), our goal is to generate actionable knowledge that will facilitate early recommendations for safe use of long-acting medicines during the perinatal period.

Georgia Duffy

Georgia obtained both a BSc (hons) in Pharmacology and a Master of Research in Biomedical Sciences and Translational Medicine (Women’s and Children’s Health) from the University of Liverpool. She is now undertaking her PhD within CELT as a member of the Perinatal Pharmacology Group. She is working on the Long-acting Antipsychotics for Mental Ill-health in Pregnancy and Postpartum (LAMP) study. The overarching aim of the multi-centre cohort study is to advance our understanding of the pharmacology of long-acting antipsychotics during pregnancy and lactation.

Mark Ryan

Mark is a Scientific Data Curator within the Perinatal Pharmacology Group. He is working on new open access initiatives aimed at facilitating access to the clinical development landscape of long-acting therapeutics, and the pharmacokinetic data of therapeutics in human pregnancy. Through these initiatives, we will support the curation of data generated from research within our group, and by collaborators and other scientists in globally representative, open access databases. Mark holds a BSc in Biochemistry and a Master of Research in Advanced Biological Sciences from the University of Liverpool. He previously worked in industry as a biocurator.

Svirarshini Chenumalla

Srivarshini has a background in biotechnology with both BSc and MSc degrees from the Osmania University College for Women, Hyderabad, and considerable wet lab experience. She is currently on the MSc Bioinformatics course here in Liverpool to broaden her knowledge and acquire new computational skills applicable to drug development. Combining her previous experiences and new knowledge from the bioinformatics course, she is exploring the use of quantitative proteomics data to optimise maternofetal PBPK modelling.

Back to: Centre of Excellence for Long-acting Therapeutics